API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
0
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
ADVANZ strengthens its specialty and hospital business by gaining an anti-infective portfolio from Sanofi made up of eight anti-infectives including Azactam (aztreonam), Cefotax, Claforan, Oroken, Rulid, Suprax, Wintriaxone and Colistimethate Sodique products.
Lead Product(s): Aztreonam
Therapeutic Area: Infections and Infectious Diseases Product Name: Azactam
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Advanz Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition October 03, 2022
Details:
ATM-AVI (aztreonam-avibactam) is an investigational treatment for infections caused by Gram-negative bacteria with limited treatment options. It combines aztreonam, a monobactam β-lactam, with avibactam, a recent broad-spectrum β-lactamase inhibitor.
Lead Product(s): Aztreonam,Avibactam,Metronidazole
Therapeutic Area: Infections and Infectious Diseases Product Name: ATM-AVI
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2023